| Name | Title | Contact Details |
|---|
Careguide Systems is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
United Medical Supply is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. United Medical Supply is based in Greensboro, NC. You can find more information on United Medical Supply at www.umedsupply.com
Physician`s Weekly (PW) is a leading source of trusted medical information, perspectives, and education for healthcare providers and patients. As pioneers in delivering medical information at the point of care, Physician`s Weekly supports over 39,000 top medical institutions and group practices across more than 20 specialties. By providing expert medical content through its print and digital products, Physician`s Weekly aims to improve the quality of communication between healthcare providers, their peers, patients, and caregivers.
Shiseido Cosmetics America Ltd. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Shiseido Cosmetics America Ltd. is based in New York, NY. You can find more information on Shiseido Cosmetics America Ltd. at www.sca.shiseido.com
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.